Acquisition of numerous patents based on BMS original know-how and technologies
Our core cell culture media technology is protected as know-how, since there are many risks involved in disclosing the composition of media.
For the above reasons, the major patents we holds are for use (patents with rights limited by the target disease) or are on manufacturing methods. Among these patents, there are rights regarding MSC being an agent that regulates diseases or gene expression, protein expression, and function associated with a disease. We plan to expand these rights to a variety of diseases. These patents can be licensed out and, accordingly, we are open to discussion at any time.
In the future, the composition of media may be subject to rights in the course of development for disease-specific media. In such circumstances, we plan to make a final decision on the acceptability of applications in consultation with companies/organizations that are interested in the media.
In the future, the composition of media may be subject to rights in the course of development and the advance of disease-specific media. In such circumstances, we plan to make a final decision on the acceptability of applications in consultation with companies and organizations that are interested in the target media.
MDPSMedium Development Platform System
- 1.Basic technology
- Development of AOF medium
- 2.Optimization technology
- Technology to optimize an AOF medium foreach disease
2-1. Database of gene expression profile in MSCs with AOF medium + hundreds of different factors
2-2. appl. No.2021-067943
2-3. Optimization technology
Anti-fibrosis/Anti-infectious disease/
Anti-neurodegenerative disease
- JP patent No.5993113Treatment for Alzheimer’s disease
- JP patent No.6132459Prevention/
Treatment for inflammatory
bowel disease - JP patent No.6611400Suppression of
Synoviolin gene expression - JP patent No.6497827Enhancement of
eicosanoids production - JP patent No.6829225Enhancement of
monoamines production - JP appl. No.2016-077695Prevention/Treatment for
inflammatory bowel disease
-
Drug candidates for anti-rheumatoid/Suppressive reagents for proliferation of synovial cells
-
Drug candidates for COVID-19
-
Anti-fibrosis
reagents -
Anti-inflammation
reagents -
Anti-infectious
reagents
culture technologies